Grace Therapeutics (GRCE) Income towards Parent Company (2019 - 2026)

Grace Therapeutics has reported Income towards Parent Company for 8 years, with the latest figure at -$1.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 1098.31% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (up 22.73% YoY) and the FY2026 annual result came in at -$7.8 million, up 22.73% from the prior year.
• Income towards Parent Company advanced to -$1.2 million in Q1 2026 per GRCE's latest filing, from -$2.3 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $118000.0 in Q1 2025 and troughed at -$38.6 million in Q1 2023.
• A 5-year average of -$5.1 million and a median of -$3.4 million in 2025 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 2072.61% in 2023, then jumped 102.53% in 2025.
• Over 5 years, Income towards Parent Company stood at -$3.9 million in 2022, then soared by 38.52% to -$2.4 million in 2023, then sank by 73.78% to -$4.2 million in 2024, then surged by 44.28% to -$2.3 million in 2025, then jumped by 49.11% to -$1.2 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$1.2 million, -$2.3 million, and -$938000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.